The FDA cancelled this meeting. The committee was scheduled to discuss new drug application sugammadex sodium injection, submitted by Organon USA Inc., for the proposed indication of reversal of moderate or deep neuromuscular blockade induced by rocuronium or vecuronium.

The meeting has been cancelled in order to allow time for the FDA to consider new information. Tarius will monitor the Federal Register and other sources for any rescheduling or further announcements regarding this meeting.